Julie M Cherrington, PhD is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®.
Dr. Cherrington has served as President and Chief Executive Officer at several biotechnology companies, including QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation, a diabetes and antiviral company. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.
Dr. Cherrington is a member of the Scientific Advisory Boards of the Clearity Foundation and Rakovina Therapeutics. She is also an advisor to several start up companies, and active in entrepreneurship initiatives through CLS, UC San Francisco, UC Davis and Equalize 2020/2021/2022.
Currently, she serves on the Boards of Syncona Ltd, Sardona Therapeutics, Kisoji Biotechnology, MycRx, QUE Oncology, Vaxart, and Mirati Therapeutics.